Saturday 17 October 2026
Export CANF’s income statement to Excel — free account
Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
1.76
0.09
−4.86%
Follow CANF
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 2 | 3 | 3 | 2 | 3 | 2 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.01 | 8.26 | 10.49 | 456.31 | 6,107.14 | 10,545.83 | 4.04 | 415.13 | 126.29 | 138.30 |
Altman Z-Score |
(27.99) | (25.57) | (22.40) | (23.32) | (8.32) | (18.54) | (21.94) | (15.77) | (13.93) | (11.22) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(61.28) | (58.92) | (50.30) | (54.60) | (18.72) | (45.48) | (50.31) | (41.24) | (40.21) | (29.33) |
P/Operating CF |
(0.11) | (0.87) | (1.11) | (49.17) | (714.06) | (1,107.37) | (0.66) | (44.40) | (3.76) | (4.19) |
Beneish M-Score |
— | — | — | — | — | (4.91) | 191.95 | (1.57) | 51.19 | 0.48 |
P/B ratio |
0.19 | 2.58 | 1.55 | 80.60 | 362.48 | 1,336.03 | 5.50 | 107.95 | 4.72 | 3.28 |
Price to Tangible BV |
0.19 | 2.58 | 1.55 | 80.60 | 362.48 | 1,336.03 | 5.50 | 107.95 | 4.72 | 3.28 |
EV/Sales |
(7.31) | 2.16 | 0.25 | 446.20 | 6,084.72 | 10,534.99 | 1.73 | 410.17 | 81.55 | 70.59 |
EV/EBITDA |
0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.28 | (0.09) | (0.01) | (15.54) | (280.89) | (361.54) | (0.12) | (19.15) | (1.06) | (0.93) |
EV/FCF |
0.28 | (0.09) | (0.01) | (15.48) | (279.57) | (360.26) | (0.12) | (19.06) | (1.05) | (0.93) |
Quick Ratio |
3.13 | 3.84 | 4.42 | 3.19 | 7.01 | 7.41 | 2.18 | 2.53 | 3.80 | 4.04 |
Current Ratio |
3.46 | 4.38 | 4.91 | 3.66 | 7.35 | 7.41 | 2.18 | 2.53 | 3.80 | 4.04 |
Net Debt/EBITDA |
0.86 | 0.97 | 1.09 | 0.79 | 1.49 | 0.59 | 0.23 | 0.72 | 0.49 | 0.94 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.07 | 0.08 | 0.05 | 0.06 | 0.09 | 0.25 | 0.49 | 0.09 | 0.01 |
Operating CF/Net income |
0.91 | 0.97 | 1.11 | 1.06 | 0.65 | 0.80 | 0.88 | 0.63 | 1.42 | 1.29 |
Capex/Depreciation |
(0.08) | (0.71) | (0.13) | (0.64) | (0.79) | (2.17) | (0.21) | (2.36) | (1.53) | (0.56) |
Interest Coverage |
— | — | — | (131.12) | 56.57 | (46.51) | (19.43) | (4.50) | (11.57) | (48.52) |
| (178.24%) | (134.94%) | (142.49%) | (107.91%) | (148.66%) | (355.99%) | (462.71%) | (163.68%) | (142.61%) | (96.34%) | |
| (105.48%) | (82.47%) | (79.22%) | (68.89%) | (102.13%) | (171.31%) | (156.58%) | (84.43%) | (71.28%) | (49.68%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (297.59%) | 0.00% |
Return on Tangible Assets |
(146.38%) | (113.27%) | (96.43%) | (151.90%) | (87.46%) | (185.28%) | (322.97%) | (136.02%) | (128.37%) | (90.11%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 505.64 | 787.30 | 383.63 | 1,461.39 | 4,279.09 |
Research and Development Expense of Revenue |
1,652.59% | 854.15% | 805.25% | 958.40% | 1,154.75% | 1,566.32% | 540.16% | 159.03% | 647.15% | 3,577.06% |
Selling, General and Administrative Expense of Revenue |
904.20% | 452.08% | 397.71% | 388.02% | 450.76% | 386.76% | 150.74% | 82.70% | 363.50% | 1,603.53% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
83.95% | 53.71% | 35.13% | 32.47% | 54.63% | 46.53% | 18.95% | 14.01% | 24.33% | 179.41% |
Graham Net Nets |
5.20 | 0.37 | 0.63 | 0.01 | 0.00 | 0.00 | (0.03) | 0.01 | 0.21 | 0.30 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(325.14%) | (39.89%) | (31.41%) | (15.26%) | (9.31%) | (40.46%) | (75.74%) | (11.63%) | (27.32%) | (21.00%) |
Free Cash Flow Yield |
(2,534.73%) | (291.06%) | (284.36%) | (6.32%) | (0.36%) | (0.28%) | (350.15%) | (5.18%) | (61.28%) | (54.95%) |
Revenue per Share |
0.49 | 1.86 | 3.49 | 5.96 | 9.25 | 12.78 | 142.10 | 587.69 | 146.11 | 36.17 |
Operating CF per Share |
(10.87) | (21.06) | (39.61) | (79.42) | (106.92) | (202.06) | (775.10) | (639.23) | (1,661.48) | (1,900.21) |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.07) | (0.12) | (0.44) | (0.21) | (5.08) | (5.37) | (2.13) |
Free Cash Flow per Share |
(10.88) | (21.07) | (39.62) | (79.49) | (107.04) | (202.50) | (775.31) | (644.31) | (1,666.85) | (1,902.34) |
Cash per Share |
10.38 | 21.75 | 41.87 | 58.73 | 207.58 | 139.75 | 193.08 | 598.15 | 649.07 | 1,726.60 |
Shareholders Equity per Share |
6.79 | 14.99 | 29.30 | 32.88 | 155.99 | 101.74 | 170.77 | 463.85 | 928.52 | 824.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.79 | 14.99 | 29.30 | 32.88 | 155.99 | 101.74 | 170.77 | 463.85 | 928.52 | 824.68 |
Free Cash Flow |
(8.95) | (7.64) | (8.44) | (10.81) | (9.87) | (12.09) | (11.09) | (4.19) | (9.00) | (8.94) |
Working Capital |
6.71 | 6.93 | 7.89 | 6.66 | 17.34 | 8.13 | 3.87 | 4.78 | 4.91 | 7.60 |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.03) | 0.00 | (0.03) | (0.03) | (0.01) |
Net Current Asset Value |
5.52 | 5.30 | 6.16 | 4.35 | 14.20 | 5.95 | 1.41 | 2.97 | 4.06 | 3.81 |
EV/EBIT |
0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.03 | 0.00 | 0.01 | 0.04 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.80 | 0.26 | 0.52 | 0.33 | 0.30 | 0.24 | 0.39 | 0.30 | 0.68 | 0.34 |
Cash ROIC |
(63.34%) | (57.36%) | (55.67%) | (86.76%) | (29.44%) | (83.85%) | (213.09%) | (60.67%) | (105.66%) | (74.56%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 17.00 | 1.54 | 0.28 | 0.48 | 1.07 | 0.31 | 0.13 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 0.05 | 0.55 | 2.72 | 4.20 | 3.59 | 2.58 | 1.31 |
Average Payables |
1.93 | 1.48 | 1.52 | 1.77 | 1.38 | 1.83 | 2.48 | 1.81 | 1.80 | 1.87 |
Average Assets |
9.32 | 9.55 | 9.64 | 14.77 | 14.89 | 8.85 | 8.06 | 7.78 | 8.89 | 13.89 |
Average Common Equity |
5.51 | 5.84 | 5.36 | 9.43 | 10.23 | 4.26 | 2.73 | 4.01 | 4.45 | 7.16 |
Columns are period end dates